Background Tuberculosis (TB) treatment monitoring relies on sputum-based microbiological assays, which are slow and provide limited insight into the host response. Blood-based biomarkers could offer rapid and minimally invasive treatment monitoring. Methods We performed an integrative multi-omics analysis of paired who...
G. V. Anoushka Chinmayi, Darla Quijada, A. Queiroz et al.· bioRxiv· 0 citations
Background Host-directed therapies may improve tuberculosis (TB) outcomes by modulating immune responses and attenuating hyperinflammation, yet accessible biomarkers remain limited. We hypothesized that interferon-γ–inducible protein 10 (IP-10/CXCL10) measured in dried blood spot (DBS), a low-threshold and field-adapte...
Iselin Høgbakk Edlund, Noelia Alonso-Rodríguez, C. Sopegno et al.· Frontiers in Immunology· 0 citations
Background: Tuberculosis (TB) remains the leading infectious disease cause of mortality worldwide. A subset of individuals exposed to Mycobacterium tuberculosis (Mtb) remain TST/IGRA-negative despite sustained exposure, termed "TB resisters". The biological mechanisms underlying this resistance remain poorly understood...
Chang Liu, Jeffrey M. Collins, M. F. Gyorfy et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.